Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Pulmonary Disease, Chronic Obstructive 1

Interventions

Carboplatin 41Cisplatin 38Paclitaxel 34Specimen Handling 32Radiotherapy 27Magnetic Resonance Spectroscopy 25Gemcitabine 23Vinorelbine 15Etoposide 15Docetaxel 15Biopsy 13Pemetrexed 10Cyclophosphamide 10pembrolizumab 9Taxes 9Immunoglobulin G 9Disulfides 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8X-Rays 7Vinblastine 7Erlotinib Hydrochloride 7osimertinib 6durvalumab 6atezolizumab 6Nivolumab 6Irinotecan 6Ifosfamide 6Chemotherapy, Adjuvant 6Celecoxib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lung Neoplasms × Iloprost × Clear all
NCT05411107 2024-05-17

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

NCT02237183 2023-11-28

Iloprost in Preventing Lung Cancer in Former Smokers

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡